Answers are grounded in this paper and cite their sources.
The Ras-Raf-MEK-ERK signaling pathway is involved in numerous cancers. Monitoring its overactivation by PET imaging remains challenging, yet it holds significant potential for personalized diagnostics. Here, we report the fluorine-18 isotopic radiolabeling of binimetinib, an FDA-approved specific allosteric MEK1/2 inhibitor, for the treatment of BRAF-positive melanoma. The inherent structure of binimetinib makes its radiolabeling a strong challenge, addressed by evaluating seven precursors using a simplified model compound. A fully automated, four-step, one-pot radiosynthesis afforded [18F]binimetinib with a 9 ± 5% radiochemical yield after 100 min with >95% radiochemical purity. In vitro evaluation of [18F]binimetinib demonstrated specific uptake in H358 cells with activated Ras-Raf-MEK-ERK. PET imaging of an H358 xenograft mouse model revealed promising tumor uptake at 4 h post-injection with 1.96 ± 0.51 % ID.cm−3 in the tumor. This study provides insight into the in vivo pharmacokinetic profile derived from PET imaging of [18F]binimetinib and its potential for investigating MEK target availability in tumors.
No takes yet. Share an insight, caveat, or question.
Pelletier et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: